IL-6 receptor antagonists and antiplatelet agents improved chances for 6-month survival among patients with COVID-19, according to study results presented at Society of Critical Care Medicine’s ...

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disorder of the optic nerves and the spinal cord that is linked to the presence of anti-aquaporin (AQP4) autoantibodies.

An IL-6 receptor inhibitor has already been developed. Now we need to use the findings from this study and others to better understand who will benefit the most from this new medication.

IL-6 triggers signal transduction after binding to the IL-6 receptor (IL-6R). [19, 20] There are two forms of IL-6R, a transmembrane 80-kDa form with a short cytoplasmic domain and a soluble form ...

One mechanism involves cis-signaling, where IL-6 interacts with its receptor on the cell surface, while the other involves trans-signaling, which uses a soluble form of IL-6 receptor.

EBI-031 was designed and engineered for intravitreal delivery using Eleven’s AMP-Rx platform. EBI-031 is a potent blocker of both free IL-6 and IL-6 complexed to the soluble IL-6 receptor (IL-6R).

Treatment with interleukin 6 (IL-6) receptor antagonists or antiplatelet agents improves survival and outcomes at 6 months for critically ill patients with COVID-19, according to new data.

A new type of anti-interleukin-6 (IL-6) biologic called olokizumab was as effective as adalimumab (Humira) in rheumatoid arthritis patients who needed a step up from methotrexate monotherapy ...

Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. European Respiratory Review 19, 46-54 (2010). DOI: 10.1183/09059180.00007609 ...